CSIMarket
 


Kymera Therapeutics Inc   (KYMR)
Other Ticker:  
 
 

KYMR's Income from Cont. Operations Growth by Quarter and Year

Kymera Therapeutics Inc 's Income from Cont. Operations results by quarter and year




KYMR Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -28.58 -7.99 0.00
III Quarter September -43.00 -24.66 0.00 0.00
II Quarter June -40.26 -13.08 0.00 0.00
I Quarter March -36.68 7.99 0.00 0.00
FY   -119.94 -58.33 -7.99 0.00



KYMR Income from Cont. Operations third quarter 2022 Y/Y Growth Comment
Kymera Therapeutics Inc in the third quarter 2022 recorded loss from continued operations of $ -43.00 millions.

According to the results reported in the third quarter 2022, Kymera Therapeutics Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Kymera Therapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2022.




KYMR Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Kymera Therapeutics Inc 's third quarter 2022 Income from Cont. Operations $ -43.00 millions KYMR's Income Statement
Kymera Therapeutics Inc 's third quarter 2021 Income from Cont. Operations $ -24.66 millions Quarterly KYMR's Income Statement
New: More KYMR's historic Income from Cont. Operations Growth >>


KYMR Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Kymera Therapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYMR's III. Quarter Q/Q Income from Cont. Operations Comment
Current loss from continued operations of -43.00 millions by Kymera Therapeutics Inc appear even worse compare to the loss from continued operations -40.26 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Kymera Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Kymera Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYMR's III. Quarter Q/Q Income from Cont. Operations Comment
Recent accomplishment of -43.00 millions by Kymera Therapeutics Inc come out even more unfavourable considering the -40.26 millions loss from continued operations in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Kymera Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Kymera Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Kymera Therapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -148.53 $ -130.18 $ -103.00 $ -58.33 $ -37.74
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Kymera Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -149 millions in the Sep 30 2022 period.
The results are worsening as the cumulative loss from continued operations is inflating from $ -130.18 millions in the twelve months ending a quarter before and $ -40.26 millions for the twelve months ending in the quarter Jun 30 2021 Charlie  P. Smith wrote.

Kymera Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Kymera Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -149 millions in the Sep 30 2022 period.
The situation is getting worse as the cumulative loss from continued operations is getting bigger from $ -130.18 millions for the period from Jun 30 2022 to Jun 30 2021 and $ -40.26 millions for the twelve months ending in the quarter a year ago Charlie  P. Smith wrote.

Kymera Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
KYMR's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for KYMR's Competitors
Income from Cont. Operations Growth for Kymera Therapeutics Inc 's Suppliers
Income from Cont. Operations Growth for KYMR's Customers

You may also want to know
KYMR's Annual Growth Rates KYMR's Profitability Ratios KYMR's Asset Turnover Ratio KYMR's Dividend Growth
KYMR's Roe KYMR's Valuation Ratios KYMR's Financial Strength Ratios KYMR's Dividend Payout Ratio
KYMR's Roa KYMR's Inventory Turnover Ratio KYMR's Growth Rates KYMR's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2022
Carlisle Companies Incorporated125.84%$ 125.841 millions
Innoviva Inc 123.43%$ 123.435 millions
Catalyst Pharmaceuticals Inc 120.23%$ 120.234 millions
Bausch Health Companies Inc 110.99%$ 110.995 millions
Lsi Industries Inc 99.87%$ 99.872 millions
Abiomed Inc 86.35%$ 86.352 millions
Stryker Corp86.30%$ 86.301 millions
Universal Security Instruments Inc86.27%$ 86.267 millions
American Shared Hospital Services83.33%$ 83.333 millions
Vir Biotechnology Inc 58.76%$ 58.757 millions
United Therapeutics Corporation47.08%$ 47.081 millions
Dexcom Inc 42.74%$ 42.736 millions
Pro dex Inc 42.14%$ 42.140 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

DTSS's Profile

Stock Price

DTSS's Financials

Business Description

Fundamentals

Charts & Quotes

DTSS's News

Suppliers

DTSS's Competitors

Customers & Markets

Economic Indicators

DTSS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071